CN103948552A - Oxcarbazepine controlled-release tablet and preparation method thereof - Google Patents
Oxcarbazepine controlled-release tablet and preparation method thereof Download PDFInfo
- Publication number
- CN103948552A CN103948552A CN201410162640.2A CN201410162640A CN103948552A CN 103948552 A CN103948552 A CN 103948552A CN 201410162640 A CN201410162640 A CN 201410162640A CN 103948552 A CN103948552 A CN 103948552A
- Authority
- CN
- China
- Prior art keywords
- cellulose
- oxcarbazepine
- release tablet
- controlled release
- controlled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention aims at providing an oxcarbazepine controlled-release tablet which is capable of releasing medicines at a constant speed, and higher in medicine release stability and medicine use safety. The oxcarbazepine controlled-release tablet is characterized by consisting of curative dose of oxcarbazepine and physiologically acceptable pharmaceutical adjuvant; the medicine can be released at the constant speed in different release media. The controlled-release tablet disclosed by the invention has the characteristics of being convenient to dose, lasting in action, stable in curative effect, small in toxic and side effect, and the like.
Description
Invention field
The present invention relates to a kind of pharmaceutical preparation for the treatment of epilepsy and preparation method thereof, belong to the medication of neurosurgery class disease, be specifically related to a kind of oxcarbazepine controlled release tablet and preparation method thereof.
Background of invention
Oxcarbazepine belongs to benzene diaza leather class medicine, is worldwide registered as antuepileptic.Oxcarbazepine goes through as being used for the treatment of adult and child's partial seizure and ancillary drug or the monotherapy of complete tetanus-clonic epilepsy outbreak.Oxcarbazepine releases (IR) dosage form with commodity masterpiece in music Lay at present
sell, use every day and control epilepsy twice.This compositions of releasing provides medicine to patient in some way, causes plasma drug level to rise rapidly, then declines rapidly.The sharp change of this drug level may cause side effect, and must every day repeatedly drug administration, to keep medicine treatment level in vivo.For the medicine of long-term taking as the controlled release form of oxcarbazepine and derivant need to be self-evident.Use controlled release (CR) dosage form of taking for example every day once greatly to improve patient compliance.And, use controlled release form to have obvious clinical advantages, for example the better side effect of therapeutic effect and minimizing.
Oxcarbazepine and derivant thereof that the present invention considers are slightly soluble in water.Poorly soluble due to them, their release from Slow release dosage form is quite incomplete.Although the vitro release of oxcarbazepine depends on dissolving-out method, comprise dissolution medium used, to find by microcomputer modelling, in the body of oxcarbazepine from conventional Slow release dosage form, release is quite low.The declined bioavailability of oral administration that this causes medicine, makes dosage form can not provide in vivo treatment effective concentration.This has proposed stern challenge for the Slow release dosage form of successfully developing oxcarbazepine and derivant thereof.
The rate of release of medicine from dosage form has appreciable impact for treatment serviceability and the side effect thereof of medicine.The Slow release dosage form of oxcarbazepine and derivant has been described in this area.Franke etc. (US20040142033) disclose the Slow release dosage form of oxcarbazepine, it is characterized in that in 15 minutes, discharging 55%-85% medicine, and in 30 minutes, discharge high to 95% medicine.Described in author, these release profiles provide sufficient Slow to release to obtain and have used oxcarbazepine every day one time.But the dissolubility and the bioavailability that strengthen the medicine of preparation from these are applicable to using once every day.
The object of this invention is to provide a kind of can constant release medicine and the stability of medicine release and the higher oxcarbazepine controlled release tablet of the safety of medication, it is characterized in that being formed by oxcarbazepine and the physiologically acceptable pharmaceutic adjuvant of effective therapeutic dose, can constant release at different release medium Chinese medicines.The features such as controlled release tablet of the present invention has that convenient drug administration, effect are lasting, stable curative effect, toxic and side effects are little.
Summary of the invention
The object of this invention is to provide a kind of can constant release medicine and the stability of medicine release and the higher oxcarbazepine controlled release tablet of the safety of medication, it is characterized in that being formed by oxcarbazepine and the physiologically acceptable pharmaceutic adjuvant of effective therapeutic dose, can constant release at different release medium Chinese medicines.The features such as controlled release tablet of the present invention has that convenient drug administration, effect are lasting, stable curative effect, toxic and side effects are little.
Oxcarbazepine controlled release tablet of the present invention, it is characterized in that being made up of oxcarbazepine and the physiologically acceptable pharmaceutic adjuvant of effective therapeutic dose, can constant release at different release medium Chinese medicines.
On the one hand, the invention provides a kind of oxcarbazepine controlled release tablet, wherein said controlled release tablet is made up of oxcarbazepine, controlled-release material, filler, binding agent, lubricant, and described oxcarbazepine consumption accounts for 10～50% of recipe quantity.
Some embodiments therein, controlled release tablet of the present invention, wherein said controlled-release material is selected from one or more in hydroxypropyl methylcellulose, ethyl cellulose, methylcellulose, Hydroxypropyl Methylcellulose Phathalate, cellulose acetate-phthalate, hydroxypropyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl-cellulose, cellulose acetate, sodium alginate, cellulose diacetate, Triafol T, glyceryl monostearate, hydroxy methocel, and described controlled-release material consumption accounts for 0～50% of recipe quantity.
Some embodiments therein, controlled release tablet of the present invention, wherein said filler is selected from microcrystalline Cellulose, mannitol, low-substituted hydroxypropyl cellulose, polyvinyl alcohol, poly-phthalic acid vinyl acetate, Polyethylene Glycol, chitosan, sucrose, lactose, starch, dextrin, Icing Sugar, crosslinked polyethylene than coughing up one or more in protective embankment ketone, cross-linking sodium carboxymethyl cellulose, pregelatinized Starch, titanium dioxide, and described filler loading accounts for 0～50% of recipe quantity.
Some embodiments therein, controlled release tablet of the present invention, wherein said binding agent is selected from one or more in water, ethanol, dehydrated alcohol, starch slurry, polyvidone, crospolyvinylpyrrolidone, hydroxypropyl methylcellulose and/or other cellulose families, and described binder dosage accounts for 0～20% of recipe quantity.
Some embodiments therein, controlled release tablet of the present invention, wherein said lubricant is selected from one or more in magnesium stearate, micropowder silica gel, Pulvis Talci, hydrogenated vegetable oil, polyethylene glycols, month extension alcohol magnesium sulfate, and described lubricant quantity accounts for 0.1～8% of recipe quantity.
Some embodiments therein, controlled release tablet of the present invention, wherein said controlled release tablet is made up of following component:
Oxcarbazepine 300g
Hypromellose 200g
Microcrystalline Cellulose 100g
Low-substituted hydroxypropyl cellulose 50g
Polyvidone 50g
Magnesium stearate 3g
Appropriate amount of ethanol
Make 1000.
On the other hand, the present invention relates to a kind of preparation method of controlled release tablet of the present invention, it comprises following steps: (1) prepares binding agent and get the binding agent of recipe quantity and make the binding agent of 10% (W/W), for subsequent use; (2) granulate after 80 orders sieve respectively by oxcarbazepine, filler, together put into mixer-granulator with controlled-release material, filler, mix, evenly, add suitable amount of adhesive to carry out wet granulation, take out the granule 20 mesh sieves granulate that wets, after oven dry, cross 20 mesh sieve granulate, for subsequent use; (3) tabletting is by the lubricant of the granule making and recipe quantity, and after mix homogeneously, detection level is determined sheet weight, tabletting.
The art for coating of oxcarbazepine controlled release tablet provided by the invention, its comprise as follows (1) or (2) Walk are rapid:
(1) get coating material, add appropriate solvent, be stirred to dissolve; Separately get porogen and put in measuring bottle, add water and make, after its dissolving, to join in above-mentioned coating material solution, limit edged stirs, and porogen is all dissolved, and adds plasticizer to shake up, and makes coating solution.The above-mentioned label making is put in seed-coating machine, and logical hot blast, maintains the temperature between 30-40 DEG C, sprays into coating solution.Be positioned in the environment of 40 DEG C and volatilize solvent, to obtain final product.
(2) recipe quantity filmogen is added in water, and it is appropriate to add water, and stirs 45 minutes, makes all to dissolve and disperse, for subsequent use.The plain sheet making is set high in effect coating pan, and inlet temperature is heated to 50 DEG C～80 DEG C left and right, at the uniform velocity sprays into coating solution coating, and sheet bed tempertaure remains on 35～45 DEG C, and coating increases weight approximately 3%, to obtain final product.
Excipient of the present invention comprises, but be not limited to, ion-exchanger, aluminum, aluminium stearate, lecithin, serum albumin, as human albumin, buffer substance is as phosphate, glycine, sorbic acid, potassium sorbate, the partial glycerol ester admixture of saturated vegetable fatty acid, water, salt or electrolyte, as protamine sulfate, sodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salt, colloid silicon, magnesium trisilicate, polyvinylpyrrolidone, polyacrylate, wax, polyethylene-polyoxypropylene-blocking-up polymer, lanoline, sugar, as lactose, dextrose plus saccharose, starch is as corn starch and potato starch, the derivant of cellulose and it is as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate, natural gum powder, Fructus Hordei Germinatus, gelatin, Pulvis Talci, adjuvant is as cocoa butter and suppository wax, oily as Oleum Arachidis hypogaeae semen, Oleum Gossypii semen, safflower oil, Oleum Sesami, olive oil, Semen Maydis oil and Oleum Glycines, glycols compound, as propylene glycol and Polyethylene Glycol, esters is as ethyl oleate and ethyl laurate, agar, buffer agent is as magnesium hydroxide and aluminium hydroxide, alginic acid, pyrogen-free water, Deng oozing salt, Lin Ge (family name) solution, ethanol, phosphate buffer solution, and other nontoxic proper lubrication agent are as sodium laurylsulfate and magnesium stearate, coloring agent, releasing agent, coating dress material, sweeting agent, flavoring agent and spice, antiseptic and antioxidant.
Pharmaceutical composition of the present invention can also optionally contain one or more diluent.The example of diluent comprises mannitol, sorbitol, biphosphate calcium dihydrate, microcrystalline Cellulose and efflorescence cellulose.Preferred diluent is microcrystalline Cellulose.Microcrystalline Cellulose can be obtained from several suppliers, comprises Avicel PH101, Avicel PH102, Avicel PH103, Avicel PH105 and Avicel PH200 that FMC Corporation manufactures.
Pharmaceutical composition of the present invention can also optionally contain disintegrating agent.Disintegrating agent can be the one in several modified starches, modified cellulose polymer or polycarboxylic acids, such as crosslinked Carboxymethyl cellulose sodium, Explotab, polacrilin potassium and calcium carboxymethylcellulose (CMCCalcium).In one embodiment, disintegrating agent is croscarmellose sodium.Croscarmellose sodium NF type A obtains with trade name " Ac-di-sol " on market.
Pharmaceutical composition of the present invention can also optionally contain one or more surfactants or wetting agent.Surfactant can be anion, cation or neutral surface active agent.Anion surfactant comprises sodium lauryl sulfate, dodecyl sodium sulfate, oleyl sodium sulfate and the sodium laurate mixing with stearate and Talcum.Cationic surfactant comprises benzalkonium chloride and alkyl trimethyl ammonium bromide.Neutral surface active agent comprises glycerol list olein, polyoxyethylene sorbitan fatty acid ester, polyvinyl alcohol and anhydro sorbitol fat.The embodiment of wetting agent comprises poloxamer, polyoxyethylene alkyl ether, castor oil derivatives and polyoxyethylene 8 stearate fat.
The present invention can also optionally join antioxidant in preparation, thereby gives its chemical stability.Antioxidant is selected from the extract of a-tocopherol, Y-tocopherol, S-tocopherol, tocopherol enrichment natural origin, sodium or calcium salt, the Vitamin C acyl cetylate of L-AA and it, amass wealth by heavy taxation propyl propionate, amass wealth by heavy taxation misery ester, amass wealth by heavy taxation sour dodecyl ester, Yoshinox BHT (BHT) and butylated hydroxyanisol (BHA).In one embodiment, antioxidant is BHT or BHA.
The preferred dosage form of drug composition of the present invention is the tablet of preparing by compression method.Described tablet can carry out film with the mixture such as hydroxypropyl cellulose and hydroxypropyl emthylcellulose, contains titanium dioxide and/or other coloring agent, such as ferrum oxide, dyestuff and Se Dian in this mixture; The mixture of polyvinyl alcohol (PVA) and Polyethylene Glycol (PEG), contains titanium dioxide and/or other coloring agent, such as ferrum oxide, dyestuff and Se Dian; Or any other suitable instant-free coating agent.Coating provides taste masked and other stability to final tablet.What commercially available film provided for Colorcon is preparation mixture of powders
.
The present invention can also add sweeting agent and/or fumet.
Detailed description of the invention
Further explain the present invention below in conjunction with embodiment, but embodiment does not limit in any form to the present invention.
Embodiment 1
Prescription:
Oxcarbazepine 300g
Hypromellose 200g
Microcrystalline Cellulose 100g
Low-substituted hydroxypropyl cellulose 50g
Polyvidone 50g
Magnesium stearate 3g
Appropriate amount of ethanol
Make 1000.
Preparation process:
1, prepare binding agent and get the polyvidone of recipe quantity and be dissolved in ethanol, make the binding agent of 10% (w/w), for subsequent use.
2, granulate after by oxcarbazepine, hypromellose, 80 orders sieve respectively; together put into mixer-granulator with hypromellose, microcrystalline Cellulose; mix; evenly, add binding agent to carry out wet granulation; take out the granule 20 mesh sieves granulate that wets; after oven dry, cross 20 mesh sieve granulate, for subsequent use.
3, tabletting is by the magnesium stearate of the granule making and recipe quantity, and after mix homogeneously, detection level is determined sheet weight, and tabletting to obtain final product.
Embodiment 2
Element tablet recipe:
Oxcarbazepine 300g
Hypromellose 100g
Microcrystalline Cellulose 100g
Mannitol 100g
Polyvidone 30g
Magnesium stearate 3g
Appropriate amount of ethanol
Make 1000.
Preparation technology:
1, prepare binding agent and get the polyvidone of recipe quantity and be dissolved in ethanol, make the binding agent of 10% (w/w), for subsequent use;
2, granulate after 80 orders sieve respectively by oxcarbazepine, mannitol, together put into mixer-granulator with hypromellose, microcrystalline Cellulose, mix, add binding agent to carry out wet granulation after evenly, take out the granule 20 mesh sieves granulate that wets.After oven dry, cross 20 mesh sieve granulate, for subsequent use.
3, tabletting is by the magnesium stearate of the granule making and recipe quantity, and after mix homogeneously, detection level is determined sheet weight, uses
φ16x7 stamping.
Embodiment 3
Prescription:
Oxcarbazepine 300g
Ethyl cellulose 150g
Microcrystalline Cellulose 120g
Lactose 80g
Polyvidone 40g
Magnesium stearate 4g
Appropriate amount of ethanol
Make 1000.
Preparation technology
1, prepare binding agent and get the polyvidone of recipe quantity and be dissolved in ethanol, make the binding agent of 10% (w/w), for subsequent use;
2, granulate after 80 orders sieve respectively by oxcarbazepine, lactose, together put into mixer-granulator with ethyl cellulose, microcrystalline Cellulose, mix; evenly, add binding agent to carry out wet granulation, take out the granule 20 mesh sieves granulate that wets, after oven dry; cross 20 mesh sieve granulate, for subsequent use.
3, tabletting is by the magnesium stearate of the granule making and recipe quantity, and after mix homogeneously, detection level is determined sheet weight, tabletting.
Biological activity test
In order to investigate release in vitro effect of the present invention, according to drug release determination method (two annex XD first methods of Chinese Pharmacopoeia version in 2005), apparatus presses dissolution method the second subtraction unit, measured the vitro release of oxcarbazepine controlled release tablet prepared by the present invention.
Taking 0.2% 12 protective embankment base metabisulfite solution 900ml as solvent, rotating speed is per minute 100 to turn, operation in accordance with the law, 2 hours, 4 hours, 8 hours with within 12 hours, get respectively solution 5ml, filter, and the instant solution that supplements same volume in process container.Measure respectively subsequent filtrate appropriate, measure according to the method under assay item, also quantitatively dilute and become the solution of every 1ml containing 10 μ g by same dissolution with solvents, be measured in the same method.
Calculate respectively the every burst size at different time.Controlled release tablet of the present invention was the burst size of 2 hours, 4 hours, 8 hours.Oxcarbazepine controlled release tablet prepared by the embodiment of the present invention, release characteristic is as shown in table 1.
Table 1 oxcarbazepine controlled release tablet of the present invention release (%)
Visible, the prepared oxcarbazepine controlled release tablet of the present invention has reached the effect of lasting, steady release in 12 hours, can effectively reduce patient's medicining times, increases medication compliance.
Claims (7)
1. an oxcarbazepine controlled release tablet, wherein said controlled release tablet is made up of oxcarbazepine, controlled-release material, filler, binding agent, lubricant, and described oxcarbazepine consumption accounts for 10～50% of recipe quantity.
2. controlled release tablet according to claim 1, wherein said controlled-release material is selected from one or more in hydroxypropyl methylcellulose, ethyl cellulose, methylcellulose, Hydroxypropyl Methylcellulose Phathalate, cellulose acetate-phthalate, hydroxypropyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl-cellulose, cellulose acetate, sodium alginate, cellulose diacetate, Triafol T, glyceryl monostearate, hydroxy methocel, and described controlled-release material consumption accounts for 0～50% of recipe quantity.
3. controlled release tablet according to claim 1, wherein said filler is selected from microcrystalline Cellulose, mannitol, low-substituted hydroxypropyl cellulose, polyvinyl alcohol, poly-phthalic acid vinyl acetate, Polyethylene Glycol, chitosan, sucrose, lactose, starch, dextrin, Icing Sugar, crosslinked polyethylene than coughing up one or more in protective embankment ketone, cross-linking sodium carboxymethyl cellulose, pregelatinized Starch, titanium dioxide, and described filler loading accounts for 0～50% of recipe quantity.
4. controlled release tablet according to claim 1, wherein said binding agent is selected from one or more in water, ethanol, dehydrated alcohol, starch slurry, polyvidone, crospolyvinylpyrrolidone, hydroxypropyl methylcellulose and/or other cellulose families, and described binder dosage accounts for 0～20% of recipe quantity.
5. controlled release tablet according to claim 1, wherein said lubricant is selected from one or more in magnesium stearate, micropowder silica gel, Pulvis Talci, hydrogenated vegetable oil, polyethylene glycols, month extension alcohol magnesium sulfate, and described lubricant quantity accounts for 0.1～8% of recipe quantity.
6. according to the controlled release tablet described in claim 1-5 any one, wherein said controlled release tablet is made up of following component:
Oxcarbazepine 300g
Hypromellose 200g
Microcrystalline Cellulose 100g
Low-substituted hydroxypropyl cellulose 50g
Polyvidone 50g
Magnesium stearate 3g
Appropriate amount of ethanol
Make 1000.
7. a preparation method for controlled release tablet described in any one in claim 1-6, it comprises following steps: (1) prepares binding agent and get the binding agent of recipe quantity and make the binding agent of 10% (W/W), for subsequent use; (2) granulate after 80 orders sieve respectively by oxcarbazepine, filler, together put into mixer-granulator with controlled-release material, filler, mix, evenly, add suitable amount of adhesive to carry out wet granulation, take out the granule 20 mesh sieves granulate that wets, after oven dry, cross 20 mesh sieve granulate, for subsequent use; (3) tabletting is by the lubricant of the granule making and recipe quantity, and after mix homogeneously, detection level is determined sheet weight, tabletting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410162640.2A CN103948552A (en) | 2014-04-22 | 2014-04-22 | Oxcarbazepine controlled-release tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410162640.2A CN103948552A (en) | 2014-04-22 | 2014-04-22 | Oxcarbazepine controlled-release tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103948552A true CN103948552A (en) | 2014-07-30 |
Family
ID=51326002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410162640.2A Pending CN103948552A (en) | 2014-04-22 | 2014-04-22 | Oxcarbazepine controlled-release tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103948552A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106727391A (en) * | 2015-11-24 | 2017-05-31 | 浙江九洲药物科技有限公司 | A kind of Oxcarbazepine sustained release tablets and preparation method thereof |
| CN111481521A (en) * | 2020-04-14 | 2020-08-04 | 上海奥科达生物医药科技有限公司 | Oxcarbazepine sustained release preparation, preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070059354A1 (en) * | 2005-07-29 | 2007-03-15 | Sankar Ramakrishnan | Sustained release dosage forms of oxcarbazepine |
| CN101489560A (en) * | 2006-04-26 | 2009-07-22 | 苏佩努斯制药公司 | Controlled released preparations of oxcarbazepine having sigmoidal release profile |
-
2014
- 2014-04-22 CN CN201410162640.2A patent/CN103948552A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070059354A1 (en) * | 2005-07-29 | 2007-03-15 | Sankar Ramakrishnan | Sustained release dosage forms of oxcarbazepine |
| CN101489560A (en) * | 2006-04-26 | 2009-07-22 | 苏佩努斯制药公司 | Controlled released preparations of oxcarbazepine having sigmoidal release profile |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106727391A (en) * | 2015-11-24 | 2017-05-31 | 浙江九洲药物科技有限公司 | A kind of Oxcarbazepine sustained release tablets and preparation method thereof |
| CN111481521A (en) * | 2020-04-14 | 2020-08-04 | 上海奥科达生物医药科技有限公司 | Oxcarbazepine sustained release preparation, preparation method and application thereof |
| CN111481521B (en) * | 2020-04-14 | 2021-04-02 | 上海奥科达生物医药科技有限公司 | Oxcarbazepine sustained release preparation, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5401327B2 (en) | Tablets with improved dissolution | |
| KR20180125574A (en) | Oral preparation with excellent elution property | |
| CN107812195B (en) | Stable pharmaceutical composition of (6S) -5-methyl-tetrahydrofolate calcium salt | |
| CN103705478B (en) | Oral tablet containing tenofovir disoproxil fumarate | |
| CN103463095A (en) | Pharmaceutical solid preparation comprising benzazepines and production method thereof | |
| NO175884B (en) | Process for preparing a pressed tablet containing methylprednisolone and a super-disintegrant | |
| CN109875972B (en) | Olmesartan medoxomil and amlodipine pharmaceutical composition | |
| CN103948560A (en) | Carbamazepine tablet and preparation method thereof | |
| CA2634006C (en) | Pharmaceutical sustained release compositions comprising liothyronine or the sodium salt of liothyronine | |
| CN105434377A (en) | Meisuoshuli tablet and preparation method thereof | |
| CN103948553A (en) | Lamotrigine sustained release tablet and preparation method of lamotrigine sustained release tablet | |
| CN103948552A (en) | Oxcarbazepine controlled-release tablet and preparation method thereof | |
| CN104906160B (en) | A kind of enteric coated preparations of erigeron breviscapus extract | |
| JP7448275B2 (en) | Orbit Azin Fumarate Enteric Coated Pellets, Method of Preparation and Use thereof | |
| CN105030717A (en) | Moxifloxacin hydrochloride film-coated tablet and preparation method thereof | |
| EP3024443A1 (en) | Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation | |
| KR100857061B1 (en) | Tablet containing vaccinium myrtillus extract and preparing method thereof | |
| CN103405394A (en) | Metoprolol tartrate sustained release tablet and preparation method thereof | |
| CN106074553A (en) | Containing sitagliptin and the pharmaceutical composition of metformin | |
| JP3007387B2 (en) | Base powder for sustained release formulation | |
| WO2017093890A1 (en) | Clobazam tablet formulation and process for its preparation | |
| CN103989671A (en) | Indometacin capsule and preparation method thereof | |
| CN103860497A (en) | Meloxicam dispersible tablet and preparation method thereof | |
| CN104288127A (en) | Allopurinol sustained release capsule and preparation method thereof | |
| CN104644601B (en) | Capecitabine tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140730 |
|
| RJ01 | Rejection of invention patent application after publication |